nodes	percent_of_prediction	percent_of_DWPC	metapath
Methocarbamol—Thrombophlebitis—Mitomycin—urinary bladder cancer	0.0252	0.0252	CcSEcCtD
Methocarbamol—Taste metallic—Methotrexate—urinary bladder cancer	0.0204	0.0204	CcSEcCtD
Methocarbamol—Nystagmus—Fluorouracil—urinary bladder cancer	0.0175	0.0175	CcSEcCtD
Methocarbamol—Drowsiness—Mitomycin—urinary bladder cancer	0.0168	0.0168	CcSEcCtD
Methocarbamol—Feeling abnormal—Valrubicin—urinary bladder cancer	0.0128	0.0128	CcSEcCtD
Methocarbamol—Vision blurred—Mitomycin—urinary bladder cancer	0.0124	0.0124	CcSEcCtD
Methocarbamol—Pain—Carboplatin—urinary bladder cancer	0.0123	0.0123	CcSEcCtD
Methocarbamol—Body temperature increased—Valrubicin—urinary bladder cancer	0.0123	0.0123	CcSEcCtD
Methocarbamol—Syncope—Mitomycin—urinary bladder cancer	0.0118	0.0118	CcSEcCtD
Methocarbamol—Leukopenia—Mitomycin—urinary bladder cancer	0.0117	0.0117	CcSEcCtD
Methocarbamol—Loss of consciousness—Mitomycin—urinary bladder cancer	0.0115	0.0115	CcSEcCtD
Methocarbamol—Body temperature increased—Carboplatin—urinary bladder cancer	0.0114	0.0114	CcSEcCtD
Methocarbamol—Pruritus—Valrubicin—urinary bladder cancer	0.011	0.011	CcSEcCtD
Methocarbamol—Confusional state—Mitomycin—urinary bladder cancer	0.0108	0.0108	CcSEcCtD
Methocarbamol—Shock—Mitomycin—urinary bladder cancer	0.0105	0.0105	CcSEcCtD
Methocarbamol—Thrombophlebitis—Fluorouracil—urinary bladder cancer	0.0105	0.0105	CcSEcCtD
Methocarbamol—Dizziness—Valrubicin—urinary bladder cancer	0.0103	0.0103	CcSEcCtD
Methocarbamol—Vomiting—Valrubicin—urinary bladder cancer	0.00988	0.00988	CcSEcCtD
Methocarbamol—Rash—Valrubicin—urinary bladder cancer	0.00979	0.00979	CcSEcCtD
Methocarbamol—Dermatitis—Valrubicin—urinary bladder cancer	0.00979	0.00979	CcSEcCtD
Methocarbamol—Headache—Valrubicin—urinary bladder cancer	0.00973	0.00973	CcSEcCtD
Methocarbamol—Amnesia—Fluorouracil—urinary bladder cancer	0.00964	0.00964	CcSEcCtD
Methocarbamol—Somnolence—Mitomycin—urinary bladder cancer	0.00951	0.00951	CcSEcCtD
Methocarbamol—Nasal congestion—Cisplatin—urinary bladder cancer	0.00943	0.00943	CcSEcCtD
Methocarbamol—Nausea—Valrubicin—urinary bladder cancer	0.00923	0.00923	CcSEcCtD
Methocarbamol—Pain—Mitomycin—urinary bladder cancer	0.00915	0.00915	CcSEcCtD
Methocarbamol—Amnesia—Cisplatin—urinary bladder cancer	0.00914	0.00914	CcSEcCtD
Methocarbamol—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00882	0.00882	CcSEcCtD
Methocarbamol—Nystagmus—Epirubicin—urinary bladder cancer	0.0085	0.0085	CcSEcCtD
Methocarbamol—Body temperature increased—Mitomycin—urinary bladder cancer	0.00846	0.00846	CcSEcCtD
Methocarbamol—Jaundice—Thiotepa—urinary bladder cancer	0.00823	0.00823	CcSEcCtD
Methocarbamol—Conjunctivitis—Thiotepa—urinary bladder cancer	0.0082	0.0082	CcSEcCtD
Methocarbamol—Nystagmus—Doxorubicin—urinary bladder cancer	0.00787	0.00787	CcSEcCtD
Methocarbamol—Dizziness—Mitomycin—urinary bladder cancer	0.00708	0.00708	CcSEcCtD
Methocarbamol—Jaundice cholestatic—Epirubicin—urinary bladder cancer	0.00691	0.00691	CcSEcCtD
Methocarbamol—Vomiting—Mitomycin—urinary bladder cancer	0.0068	0.0068	CcSEcCtD
Methocarbamol—Conjunctivitis—Fluorouracil—urinary bladder cancer	0.00678	0.00678	CcSEcCtD
Methocarbamol—Rash—Mitomycin—urinary bladder cancer	0.00675	0.00675	CcSEcCtD
Methocarbamol—Dermatitis—Mitomycin—urinary bladder cancer	0.00674	0.00674	CcSEcCtD
Methocarbamol—Headache—Mitomycin—urinary bladder cancer	0.0067	0.0067	CcSEcCtD
Methocarbamol—Conjunctivitis—Cisplatin—urinary bladder cancer	0.00643	0.00643	CcSEcCtD
Methocarbamol—Jaundice cholestatic—Doxorubicin—urinary bladder cancer	0.0064	0.0064	CcSEcCtD
Methocarbamol—Nausea—Mitomycin—urinary bladder cancer	0.00636	0.00636	CcSEcCtD
Methocarbamol—Vision blurred—Thiotepa—urinary bladder cancer	0.00621	0.00621	CcSEcCtD
Methocarbamol—Coordination abnormal—Epirubicin—urinary bladder cancer	0.00619	0.00619	CcSEcCtD
Methocarbamol—Bradycardia—Cisplatin—urinary bladder cancer	0.00605	0.00605	CcSEcCtD
Methocarbamol—Jaundice—Etoposide—urinary bladder cancer	0.00591	0.00591	CcSEcCtD
Methocarbamol—Leukopenia—Thiotepa—urinary bladder cancer	0.0059	0.0059	CcSEcCtD
Methocarbamol—Coordination abnormal—Doxorubicin—urinary bladder cancer	0.00572	0.00572	CcSEcCtD
Methocarbamol—Convulsion—Thiotepa—urinary bladder cancer	0.00571	0.00571	CcSEcCtD
Methocarbamol—Flushing—Cisplatin—urinary bladder cancer	0.00551	0.00551	CcSEcCtD
Methocarbamol—Thrombophlebitis—Methotrexate—urinary bladder cancer	0.00544	0.00544	CcSEcCtD
Methocarbamol—Confusional state—Thiotepa—urinary bladder cancer	0.00543	0.00543	CcSEcCtD
Methocarbamol—Vision blurred—Fluorouracil—urinary bladder cancer	0.00514	0.00514	CcSEcCtD
Methocarbamol—Thrombophlebitis—Epirubicin—urinary bladder cancer	0.00509	0.00509	CcSEcCtD
Methocarbamol—Flushing—Etoposide—urinary bladder cancer	0.00505	0.00505	CcSEcCtD
Methocarbamol—Leukopenia—Gemcitabine—urinary bladder cancer	0.00497	0.00497	CcSEcCtD
Methocarbamol—Leukopenia—Fluorouracil—urinary bladder cancer	0.00488	0.00488	CcSEcCtD
Methocarbamol—Vision blurred—Cisplatin—urinary bladder cancer	0.00487	0.00487	CcSEcCtD
Methocarbamol—Somnolence—Thiotepa—urinary bladder cancer	0.00478	0.00478	CcSEcCtD
Methocarbamol—Dyspepsia—Thiotepa—urinary bladder cancer	0.00474	0.00474	CcSEcCtD
Methocarbamol—Convulsion—Fluorouracil—urinary bladder cancer	0.00473	0.00473	CcSEcCtD
Methocarbamol—Thrombophlebitis—Doxorubicin—urinary bladder cancer	0.00471	0.00471	CcSEcCtD
Methocarbamol—Dysgeusia—Etoposide—urinary bladder cancer	0.00464	0.00464	CcSEcCtD
Methocarbamol—Leukopenia—Cisplatin—urinary bladder cancer	0.00463	0.00463	CcSEcCtD
Methocarbamol—Pain—Thiotepa—urinary bladder cancer	0.0046	0.0046	CcSEcCtD
Methocarbamol—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00453	0.00453	CcSEcCtD
Methocarbamol—Confusional state—Fluorouracil—urinary bladder cancer	0.00449	0.00449	CcSEcCtD
Methocarbamol—Convulsion—Cisplatin—urinary bladder cancer	0.00448	0.00448	CcSEcCtD
Methocarbamol—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00445	0.00445	CcSEcCtD
Methocarbamol—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00444	0.00444	CcSEcCtD
Methocarbamol—Diplopia—Epirubicin—urinary bladder cancer	0.00441	0.00441	CcSEcCtD
Methocarbamol—Urticaria—Thiotepa—urinary bladder cancer	0.00428	0.00428	CcSEcCtD
Methocarbamol—Vertigo—Etoposide—urinary bladder cancer	0.00426	0.00426	CcSEcCtD
Methocarbamol—Body temperature increased—Thiotepa—urinary bladder cancer	0.00425	0.00425	CcSEcCtD
Methocarbamol—Leukopenia—Etoposide—urinary bladder cancer	0.00424	0.00424	CcSEcCtD
Methocarbamol—Hypotension—Gemcitabine—urinary bladder cancer	0.00423	0.00423	CcSEcCtD
Methocarbamol—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00422	0.00422	CcSEcCtD
Methocarbamol—Loss of consciousness—Etoposide—urinary bladder cancer	0.00416	0.00416	CcSEcCtD
Methocarbamol—Hypotension—Fluorouracil—urinary bladder cancer	0.00416	0.00416	CcSEcCtD
Methocarbamol—Convulsion—Etoposide—urinary bladder cancer	0.0041	0.0041	CcSEcCtD
Methocarbamol—Insomnia—Gemcitabine—urinary bladder cancer	0.00409	0.00409	CcSEcCtD
Methocarbamol—Diplopia—Doxorubicin—urinary bladder cancer	0.00408	0.00408	CcSEcCtD
Methocarbamol—Insomnia—Fluorouracil—urinary bladder cancer	0.00403	0.00403	CcSEcCtD
Methocarbamol—Somnolence—Gemcitabine—urinary bladder cancer	0.00402	0.00402	CcSEcCtD
Methocarbamol—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00397	0.00397	CcSEcCtD
Methocarbamol—Somnolence—Fluorouracil—urinary bladder cancer	0.00396	0.00396	CcSEcCtD
Methocarbamol—Hypotension—Cisplatin—urinary bladder cancer	0.00394	0.00394	CcSEcCtD
Methocarbamol—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00392	0.00392	CcSEcCtD
Methocarbamol—Confusional state—Etoposide—urinary bladder cancer	0.0039	0.0039	CcSEcCtD
Methocarbamol—Pain—Gemcitabine—urinary bladder cancer	0.00387	0.00387	CcSEcCtD
Methocarbamol—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00387	0.00387	CcSEcCtD
Methocarbamol—Pruritus—Thiotepa—urinary bladder cancer	0.00381	0.00381	CcSEcCtD
Methocarbamol—Pain—Fluorouracil—urinary bladder cancer	0.00381	0.00381	CcSEcCtD
Methocarbamol—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00373	0.00373	CcSEcCtD
Methocarbamol—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00367	0.00367	CcSEcCtD
Methocarbamol—Drowsiness—Methotrexate—urinary bladder cancer	0.00363	0.00363	CcSEcCtD
Methocarbamol—Hypotension—Etoposide—urinary bladder cancer	0.00361	0.00361	CcSEcCtD
Methocarbamol—Pain—Cisplatin—urinary bladder cancer	0.00361	0.00361	CcSEcCtD
Methocarbamol—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00358	0.00358	CcSEcCtD
Methocarbamol—Dizziness—Thiotepa—urinary bladder cancer	0.00356	0.00356	CcSEcCtD
Methocarbamol—Urticaria—Fluorouracil—urinary bladder cancer	0.00354	0.00354	CcSEcCtD
Methocarbamol—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00353	0.00353	CcSEcCtD
Methocarbamol—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00352	0.00352	CcSEcCtD
Methocarbamol—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00348	0.00348	CcSEcCtD
Methocarbamol—Somnolence—Etoposide—urinary bladder cancer	0.00344	0.00344	CcSEcCtD
Methocarbamol—Vomiting—Thiotepa—urinary bladder cancer	0.00342	0.00342	CcSEcCtD
Methocarbamol—Drowsiness—Epirubicin—urinary bladder cancer	0.0034	0.0034	CcSEcCtD
Methocarbamol—Rash—Thiotepa—urinary bladder cancer	0.00339	0.00339	CcSEcCtD
Methocarbamol—Dermatitis—Thiotepa—urinary bladder cancer	0.00339	0.00339	CcSEcCtD
Methocarbamol—Headache—Thiotepa—urinary bladder cancer	0.00337	0.00337	CcSEcCtD
Methocarbamol—Body temperature increased—Cisplatin—urinary bladder cancer	0.00334	0.00334	CcSEcCtD
Methocarbamol—Jaundice—Epirubicin—urinary bladder cancer	0.00331	0.00331	CcSEcCtD
Methocarbamol—Pain—Etoposide—urinary bladder cancer	0.00331	0.00331	CcSEcCtD
Methocarbamol—Conjunctivitis—Epirubicin—urinary bladder cancer	0.0033	0.0033	CcSEcCtD
Methocarbamol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00328	0.00328	CcSEcCtD
Methocarbamol—Pruritus—Gemcitabine—urinary bladder cancer	0.0032	0.0032	CcSEcCtD
Methocarbamol—Nausea—Thiotepa—urinary bladder cancer	0.0032	0.0032	CcSEcCtD
Methocarbamol—Feeling abnormal—Etoposide—urinary bladder cancer	0.00319	0.00319	CcSEcCtD
Methocarbamol—Pruritus—Fluorouracil—urinary bladder cancer	0.00315	0.00315	CcSEcCtD
Methocarbamol—Drowsiness—Doxorubicin—urinary bladder cancer	0.00314	0.00314	CcSEcCtD
Methocarbamol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00311	0.00311	CcSEcCtD
Methocarbamol—Bradycardia—Epirubicin—urinary bladder cancer	0.00311	0.00311	CcSEcCtD
Methocarbamol—Urticaria—Etoposide—urinary bladder cancer	0.00307	0.00307	CcSEcCtD
Methocarbamol—Jaundice—Doxorubicin—urinary bladder cancer	0.00306	0.00306	CcSEcCtD
Methocarbamol—Body temperature increased—Etoposide—urinary bladder cancer	0.00306	0.00306	CcSEcCtD
Methocarbamol—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.00306	0.00306	CcSEcCtD
Methocarbamol—Dizziness—Fluorouracil—urinary bladder cancer	0.00294	0.00294	CcSEcCtD
Methocarbamol—Vomiting—Gemcitabine—urinary bladder cancer	0.00288	0.00288	CcSEcCtD
Methocarbamol—Bradycardia—Doxorubicin—urinary bladder cancer	0.00287	0.00287	CcSEcCtD
Methocarbamol—Rash—Gemcitabine—urinary bladder cancer	0.00285	0.00285	CcSEcCtD
Methocarbamol—Dermatitis—Gemcitabine—urinary bladder cancer	0.00285	0.00285	CcSEcCtD
Methocarbamol—Hypersensitivity—Etoposide—urinary bladder cancer	0.00285	0.00285	CcSEcCtD
Methocarbamol—Headache—Gemcitabine—urinary bladder cancer	0.00284	0.00284	CcSEcCtD
Methocarbamol—Flushing—Epirubicin—urinary bladder cancer	0.00283	0.00283	CcSEcCtD
Methocarbamol—Vomiting—Fluorouracil—urinary bladder cancer	0.00283	0.00283	CcSEcCtD
Methocarbamol—Rash—Fluorouracil—urinary bladder cancer	0.00281	0.00281	CcSEcCtD
Methocarbamol—Dermatitis—Fluorouracil—urinary bladder cancer	0.0028	0.0028	CcSEcCtD
Methocarbamol—Headache—Fluorouracil—urinary bladder cancer	0.00279	0.00279	CcSEcCtD
Methocarbamol—Dysgeusia—Methotrexate—urinary bladder cancer	0.00278	0.00278	CcSEcCtD
Methocarbamol—Pruritus—Etoposide—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Methocarbamol—Nausea—Gemcitabine—urinary bladder cancer	0.00269	0.00269	CcSEcCtD
Methocarbamol—Vomiting—Cisplatin—urinary bladder cancer	0.00268	0.00268	CcSEcCtD
Methocarbamol—Vision blurred—Methotrexate—urinary bladder cancer	0.00267	0.00267	CcSEcCtD
Methocarbamol—Rash—Cisplatin—urinary bladder cancer	0.00266	0.00266	CcSEcCtD
Methocarbamol—Dermatitis—Cisplatin—urinary bladder cancer	0.00266	0.00266	CcSEcCtD
Methocarbamol—Nausea—Fluorouracil—urinary bladder cancer	0.00264	0.00264	CcSEcCtD
Methocarbamol—Flushing—Doxorubicin—urinary bladder cancer	0.00262	0.00262	CcSEcCtD
Methocarbamol—Dysgeusia—Epirubicin—urinary bladder cancer	0.0026	0.0026	CcSEcCtD
Methocarbamol—Dizziness—Etoposide—urinary bladder cancer	0.00256	0.00256	CcSEcCtD
Methocarbamol—Vertigo—Methotrexate—urinary bladder cancer	0.00255	0.00255	CcSEcCtD
Methocarbamol—Leukopenia—Methotrexate—urinary bladder cancer	0.00254	0.00254	CcSEcCtD
Methocarbamol—Nausea—Cisplatin—urinary bladder cancer	0.00251	0.00251	CcSEcCtD
Methocarbamol—Vision blurred—Epirubicin—urinary bladder cancer	0.0025	0.0025	CcSEcCtD
Methocarbamol—Convulsion—Methotrexate—urinary bladder cancer	0.00246	0.00246	CcSEcCtD
Methocarbamol—Vomiting—Etoposide—urinary bladder cancer	0.00246	0.00246	CcSEcCtD
Methocarbamol—Rash—Etoposide—urinary bladder cancer	0.00244	0.00244	CcSEcCtD
Methocarbamol—Dermatitis—Etoposide—urinary bladder cancer	0.00244	0.00244	CcSEcCtD
Methocarbamol—Headache—Etoposide—urinary bladder cancer	0.00242	0.00242	CcSEcCtD
Methocarbamol—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00241	0.00241	CcSEcCtD
Methocarbamol—Vertigo—Epirubicin—urinary bladder cancer	0.00239	0.00239	CcSEcCtD
Methocarbamol—Syncope—Epirubicin—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Methocarbamol—Leukopenia—Epirubicin—urinary bladder cancer	0.00238	0.00238	CcSEcCtD
Methocarbamol—Confusional state—Methotrexate—urinary bladder cancer	0.00233	0.00233	CcSEcCtD
Methocarbamol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00233	0.00233	CcSEcCtD
Methocarbamol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Methocarbamol—Vision blurred—Doxorubicin—urinary bladder cancer	0.00232	0.00232	CcSEcCtD
Methocarbamol—Convulsion—Epirubicin—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Methocarbamol—Nausea—Etoposide—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Methocarbamol—Vertigo—Doxorubicin—urinary bladder cancer	0.00221	0.00221	CcSEcCtD
Methocarbamol—Syncope—Doxorubicin—urinary bladder cancer	0.0022	0.0022	CcSEcCtD
Methocarbamol—Leukopenia—Doxorubicin—urinary bladder cancer	0.0022	0.0022	CcSEcCtD
Methocarbamol—Confusional state—Epirubicin—urinary bladder cancer	0.00219	0.00219	CcSEcCtD
Methocarbamol—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00217	0.00217	CcSEcCtD
Methocarbamol—Hypotension—Methotrexate—urinary bladder cancer	0.00216	0.00216	CcSEcCtD
Methocarbamol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00216	0.00216	CcSEcCtD
Methocarbamol—Shock—Epirubicin—urinary bladder cancer	0.00213	0.00213	CcSEcCtD
Methocarbamol—Convulsion—Doxorubicin—urinary bladder cancer	0.00213	0.00213	CcSEcCtD
Methocarbamol—Insomnia—Methotrexate—urinary bladder cancer	0.00209	0.00209	CcSEcCtD
Methocarbamol—Somnolence—Methotrexate—urinary bladder cancer	0.00206	0.00206	CcSEcCtD
Methocarbamol—Dyspepsia—Methotrexate—urinary bladder cancer	0.00204	0.00204	CcSEcCtD
Methocarbamol—Hypotension—Epirubicin—urinary bladder cancer	0.00203	0.00203	CcSEcCtD
Methocarbamol—Confusional state—Doxorubicin—urinary bladder cancer	0.00202	0.00202	CcSEcCtD
Methocarbamol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00201	0.00201	CcSEcCtD
Methocarbamol—Pain—Methotrexate—urinary bladder cancer	0.00198	0.00198	CcSEcCtD
Methocarbamol—Shock—Doxorubicin—urinary bladder cancer	0.00197	0.00197	CcSEcCtD
Methocarbamol—Insomnia—Epirubicin—urinary bladder cancer	0.00196	0.00196	CcSEcCtD
Methocarbamol—Somnolence—Epirubicin—urinary bladder cancer	0.00193	0.00193	CcSEcCtD
Methocarbamol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00191	0.00191	CcSEcCtD
Methocarbamol—Dyspepsia—Epirubicin—urinary bladder cancer	0.00191	0.00191	CcSEcCtD
Methocarbamol—Hypotension—Doxorubicin—urinary bladder cancer	0.00187	0.00187	CcSEcCtD
Methocarbamol—Pain—Epirubicin—urinary bladder cancer	0.00185	0.00185	CcSEcCtD
Methocarbamol—Urticaria—Methotrexate—urinary bladder cancer	0.00184	0.00184	CcSEcCtD
Methocarbamol—Body temperature increased—Methotrexate—urinary bladder cancer	0.00183	0.00183	CcSEcCtD
Methocarbamol—Insomnia—Doxorubicin—urinary bladder cancer	0.00181	0.00181	CcSEcCtD
Methocarbamol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00179	0.00179	CcSEcCtD
Methocarbamol—Somnolence—Doxorubicin—urinary bladder cancer	0.00178	0.00178	CcSEcCtD
Methocarbamol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00177	0.00177	CcSEcCtD
Methocarbamol—Urticaria—Epirubicin—urinary bladder cancer	0.00172	0.00172	CcSEcCtD
Methocarbamol—Pain—Doxorubicin—urinary bladder cancer	0.00171	0.00171	CcSEcCtD
Methocarbamol—Body temperature increased—Epirubicin—urinary bladder cancer	0.00171	0.00171	CcSEcCtD
Methocarbamol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00171	0.00171	CcSEcCtD
Methocarbamol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00165	0.00165	CcSEcCtD
Methocarbamol—Pruritus—Methotrexate—urinary bladder cancer	0.00164	0.00164	CcSEcCtD
Methocarbamol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.0016	0.0016	CcSEcCtD
Methocarbamol—Urticaria—Doxorubicin—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Methocarbamol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Methocarbamol—Pruritus—Epirubicin—urinary bladder cancer	0.00153	0.00153	CcSEcCtD
Methocarbamol—Dizziness—Methotrexate—urinary bladder cancer	0.00153	0.00153	CcSEcCtD
Methocarbamol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00148	0.00148	CcSEcCtD
Methocarbamol—Vomiting—Methotrexate—urinary bladder cancer	0.00147	0.00147	CcSEcCtD
Methocarbamol—Rash—Methotrexate—urinary bladder cancer	0.00146	0.00146	CcSEcCtD
Methocarbamol—Dermatitis—Methotrexate—urinary bladder cancer	0.00146	0.00146	CcSEcCtD
Methocarbamol—Headache—Methotrexate—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Methocarbamol—Dizziness—Epirubicin—urinary bladder cancer	0.00143	0.00143	CcSEcCtD
Methocarbamol—Pruritus—Doxorubicin—urinary bladder cancer	0.00142	0.00142	CcSEcCtD
Methocarbamol—Vomiting—Epirubicin—urinary bladder cancer	0.00138	0.00138	CcSEcCtD
Methocarbamol—Nausea—Methotrexate—urinary bladder cancer	0.00138	0.00138	CcSEcCtD
Methocarbamol—Rash—Epirubicin—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Methocarbamol—Dermatitis—Epirubicin—urinary bladder cancer	0.00137	0.00137	CcSEcCtD
Methocarbamol—Headache—Epirubicin—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Methocarbamol—Dizziness—Doxorubicin—urinary bladder cancer	0.00133	0.00133	CcSEcCtD
Methocarbamol—Nausea—Epirubicin—urinary bladder cancer	0.00129	0.00129	CcSEcCtD
Methocarbamol—Vomiting—Doxorubicin—urinary bladder cancer	0.00127	0.00127	CcSEcCtD
Methocarbamol—Rash—Doxorubicin—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Methocarbamol—Dermatitis—Doxorubicin—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Methocarbamol—Headache—Doxorubicin—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Methocarbamol—Nausea—Doxorubicin—urinary bladder cancer	0.00119	0.00119	CcSEcCtD
